News
In the Phase III VISIONARY study, sibeprenlimab, an investigational monoclonal antibody, showed a 51.2% reduction in ...
New data from the IRAKLIA and IZALCO trials, presented at the 2025 ASCO Annual Meeting, demonstrate that subcutaneous ...
In this video interview, Jim Kremidas, executive director, Association for MultiSite Research Corporations (AMRC), talks ...
Case study highlights how clinical operations teams can overcome complex regulatory and operational hurdles to finish a trial ...
Results from the Phase Ib/II CARTITUDE-1 trial demonstrated that a single infusion of Carvykti delivered durable, ...
In this video interview, Jim Kremidas, executive director, Association for MultiSite Research Corporations (AMRC), highlights opportunities to improve upon inefficiencies that currently exist in ...
Despite positive results from a Phase I/II trial of its investigational pandemic influenza vaccine, mRNA-1018, Moderna’s ...
In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease ...
In this video interview, Jim Kremidas, executive director, Association for MultiSite Research Corporations (AMRC), discusses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback